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1684-1182/Copyright ª 2015, TaiwanAbstract Background/purpose: The purpose of this study is to describe clinical characteris-
tics of Salmonella bacteremia in adult patients and analyze ciprofloxacin-nonsusceptible iso-
lates.
Methods: A total of 101 Salmonella blood isolates from adult patients were collected from
January 2011 to December 2013 in MacKay Memorial Hospital. Eight ciprofloxacin-
nonsusceptible Salmonella blood isolates were screened for carbapenemase and other b lacta-
mase genes. Isolates were examined by PCR for the quinolone resistance-determining region
(QRDR) of all subunits for DNA gyrase (gyrA and gyrB) genes and topoisomerase IV (parC and
parE ) genes.
Results: There were 22 (21.78%) S. enterica serovar B, 5 (4.95%) S. enterica serovar C1, 7
(6.93%) S. enterica serovar C2, 65 (64.36%) S. enterica serovar D, and 2 (1.98%) S. enterica ser-
ovar Typhi (S. typhi) isolates. b-lactamase gene screening and sequencing yielded only one
blaCMY-2-positive isolate. In multivariate risk factor analysis, renal insufficiency [odds rationfectious Diseases, Department of Internal Medicine, MacKay Memorial Hospital, Number 92, Section
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Ciprofloxacin-nonsusceptible Salmonella bacteremia 693(OR) 3.774; p Z 0.020] and heart disease (OR 2.922; p Z 0.027) were more common among
elderly patients (65 years). Independent risk factors for ciprofloxacin-nonsusceptible strains
included S. enterica serovar C2 (OR 28.430; p Z 0.032), renal insufficiency (OR 13.927;
p Z 0.032), and immunosuppression agent usage (OR 60.082; p Z 0.006). 87.50% (7/8) of iso-
lates had gyrA mutation, 62.50% (5/8) had parC mutation, and none had gyrB and parE muta-
tions. Isolates with both Ser83Phe/Asp87Asn gyrA and Thr57Ser/Ser80Ile parC mutation genes
were highly ciprofloxacin-resistant (minimum inhibitory concentration 4 mg/L).
Conclusions: Elderly patients with renal insufficiency and heart disease were at risk for Salmo-
nella bacteremia. Those for ciprofloxacin-nonsusceptible strains included S. enterica serovar
C2, renal insufficiency, and immunosuppression agent usage. The 8 ciprofloxacin-
nonsusceptible isolates carried gyrA and parC mutations, which cause resistance that poses
a major concern.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Salmonella infection is an important public health problem
worldwide. The burden is significant, with an estimated
93.8 million cases globally and 155,000 deaths each year.1,2
The average number of annual incidences of bacteremia
due to Salmonella species is 103 cases per million in-
habitants in southern Taiwan.3 Salmonella bacteremia is
usually identified by the following serogroups in microbio-
logical laboratories: S. enterica serovar B, S. enterica
serovar C1, S. enterica serovar C2, S. enterica serovar D,
and S. enterica serovar Typhi.4
Lee et al5 revealed that bacteremia due to nontyphoidal
Salmonella presented with different clinical features in
adults than it did in children. Nontyphoidal Salmonella
bacteremia in children rarely caused fatalities, whereas it
should be considered life-threatening in adult patients,
regardless of primary or secondary bacteremia.6 Salmonella
bacteremia has important clinical significance because it
affects patients who usually have underlying diseases, such
as an immunocompromised status, connective tissue dis-
eases, use of therapeutic immunosuppressants, systemic
lupus erythematosus, malignancies, diabetes mellitus, and
human immunodeficiency virus infection.59
When an invasive or severe Salmonella infection is
encountered, ceftriaxone is recommended.10 Much evi-
dence indicates that the resistance to third-generation
cephalosporins poses a major concern for use as an
empiric antimicrobial therapy for Salmonella infec-
tion.1012
DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC
and parE ) are the principal targets for antibacterial ac-
tivity of quinolones. One mechanism that has been widely
reported and associated with ciprofloxacin-resistance is
mutations in target genes in the quinolone resistance-
determining region (QRDR). Mutations at codon Ser83 or
Asp87 are known to be common sites of mutation in gyrA,
resulting in quinolone resistance. The gyrA mutations could
be detected as Ser83Phe, Ser83Tyr, and Asp87Asn, while
parC mutations are detected as Thr57Ser and Ser80Ile.1315
The risk factors of Salmonella bacteremia have been
reported around the world in recent years.5,6,7,16 However,there are currently only a few articles reporting informa-
tion concerning elderly patients and ciprofloxacin-
nonsusceptible strains with Salmonella bacteremia. The
purpose of this study is to describe the clinical character-
istics of adult patients with Salmonella bacteremia and to
analyze the ciprofloxacin-nonsusceptible isolates.Methods
Bacterial isolate collection, ciprofloxacin and
ceftriaxone susceptibility testing, and patient
characteristics
The 101 Salmonella blood isolates from patients aged 18
years were collected from January 2011 to December 2013
in MacKay Memorial Hospital, a 2200-bed hospital in
Taiwan. For patients with 2 positive blood cultures, only
the first isolate was included. Identification was performed
using the Vitek 2 system (bioMe´rieux Vitek Systems Inc.,
Hazelwood, MO, USA). O antisera was determined by the
slide agglutination test by Difco antisera (Becton Dickinson,
MD, USA) and used to identify the S. enterica isolates as
serogroups A, B, C1, C2, D, and Typhi.
Susceptibility tests for ciprofloxacin and ceftriaxone
were also performed using the Vitek 2 system. Isolates were
kept frozen at 70C in trypticase soy broth (Becton Dick-
inson) containing 20% glycerol (v/v) until further testing. In
addition, antibiotics susceptibilities against ciprofloxacin
was also determined by the agar dilution method. The
minimum inhibitory concentrations (MICs) of ciprofloxacin
and ceftriaxone were interpreted according to the Clinical
and Laboratory Standards Institute guidelines.17,18
Medical records were reviewed, and the following data
were collected: patient characteristics, comorbidities, inva-
sive procedure use (Table 1), and whether or not the patient
was in the intensive care unit (ICU) at the time of bacteremia
onset. Central line-associated infection was defined accord-
ing to the United States Centers for Disease Control and
Prevention guidelines.19 Liver cirrhosis was diagnosed by
gastroenterologists based on laboratory and radiological ev-
idence. Renal insufficiency was defined as an estimated
694 M.-W. Cheng et al.glomerular filtration rate less than 60 mL/min/1.73 m2.
Attributable mortality indicated that a patient died during
the admission period of a Salmonella bacteremia episode.
This studywas approved by theMacKayMemorial Institutional
Review Board with protocol number 14MMHIS131.Pulse-field gel electrophoresis
The eight ciprofloxacin-nonsusceptible Salmonella isolates
were identified by pulse-field gel electrophoresis (PFGE)
following the digestion of intact genomic DNA with XbaI
(Biolabs, Beverly, MA, USA). The DNA fragments were
separated on 1% (w/v) SeaKem GTG agarose gels in 0.5%
TBE [Tris-borate ethylene diamine tetra-acetic acid (EDTA)]
buffer. This was done in a CHEF Mapper apparatus (Bio-Rad,
Hercules, CA, USA) with a potential of 6 V/cm pulsed from
2.16 seconds to 63.8 seconds for 19 hours at 14C.20 The
completed gels were stained with ethidium bromide and
photographed with ultraviolet light.
The XbaI restriction profiles were initially compared to
each other by visual inspection, and isolates were consid-
ered to be closely related if they showed differences of lessTable 1 Demographic and clinical characteristics according to
patients with Salmonella enterica bacteremia.
Demographic and
clinical characteristics
n (%)
65 y <65 y
n Z 49 n Z 52
n (%) n (%)
Age, ya 62.81  18.65 78.22  7.504 48.29  13.
Sex male 64 (63.37) 32 (65.31) 32 (61.54)
Mortality 18 (17.82) 8 (16.33) 10 (19.23)
Serovar B 22 (21.78) 15 (30.61) 7 (13.46)
Serovar C1 5 (4.95) 2 (4.08) 3 (5.77)
Serovar C2 7 (6.93) 6 (12.24) 1 (1.92)
Serovar D 65 (64.36) 26 (53.06) 39 (75.00)
Serovar Typhi 2 (1.98) 0 (0.00) 2 (3.85)
CIP-ns 8 (7.92) 4 (8.16) 4 (7.69)
CRO-r 1 (0.99) 1 (2.04) 0 (0.00)
ICU stay 20 (19.8) 9 (18.37) 11 (21.15)
CVA 5 (4.95) 4 (8.16) 1 (1.92)
Heart disease 30 (29.70) 20 (40.82) 10 (19.23)
COPD 7 (6.93) 5 (10.20) 2 (3.85)
Liver cirrhosis 11 (10.89) 6 (12.24) 5 (9.62)
Renal insufficiency 20 (19.8) 14 (28.57) 6 (11.54)
Alcoholism 6 (5.94) 1 (2.04) 5 (9.62)
Malignancy 34 (33.66) 18 (36.73) 16 (30.77)
Shock within 3 d 5 (4.95) 2 (4.08) 3 (5.77)
Collagen disease 2 (1.98) 0 (0.00) 2 (3.85)
DM 29 (28.71) 18 (36.73) 11 (21.15)
Immunosuppression agent 5 (4.95) 1 (2.04) 4 (7.69)
Steroid use 6 (5.94) 1 (2.04) 5 (9.62)
Foley 21 (20.79) 10 (20.41) 11 (21.15)
CVC 18 (17.82) 8 (16.33) 10 (19.23)
a Data are presented as mean  standard deviation for age. CIP-
pulmonary disease; CRO-r Z ceftriaxone-resistant; CVA Z cerebrova
mellitus; ICU Z intensive care unit; Serovar BZ Salmonella enterica
C2Z Salmonella enterica serovar C2; Serovar D Z Salmonella enteric
d Z not available.than three bands.21 Computer-assisted analysis was also
performed using BioNumerics (Applied Maths, Sint-Martens-
Latem, Belgium). Cluster analysis was performed by the
unweighted pair group method with mathematical aver-
aging, and DNA relatedness was calculated using the band-
based Dice coefficient with 1.0% band tolerance and a
1.56% optimization setting for the whole profile. Isolates
were considered to belong to the same cluster when the
similarity coefficient reached 85%.Polymerase chain reaction (PCR) and sequencing
The eight ciprofloxacin-nonsusceptible Salmonella blood
isolates were examined by PCR for QRDR of all subunits for
DNA gyrase (gyrA and gyrB) genes and topoisomerase IV
(parC and parE ) genes using published primers.13,15
The PCR preparation procedure is outlined as follows.
Bacteria were boiled in sterile water for 10 minutes, and
the supernatant was collected and used as DNA sources for
PCR. The 25 mL reaction mixture consisted of 1X S-T Gold
buffer, 1.5mM MgCl2, 0.2mM deoxynucleotides (dNTP), and
20 pmol of each primer. The PCR amplicons were purifiedvariables of age and ciprofloxacin susceptibility among 101
P CIP-nonsusceptible CIP-susceptible p
n Z 8 n Z 93
n (%) n (%)
627 <0.01 64.88  11.544 62.63  19.171 0.746
0.852 4 (50.00) 60 (64.52) 0.460
0.904 1 (12.50) 17 (18.28) >0.99
0.065 1 (12.50) 21 (22.58) 0.682
>0.99 2 (25.00) 3 (3.23) 0.049
0.055 3 (37.50) 4 (4.30) 0.010
0.036 2 (25.00) 63 (67.74) 0.023
0.495 0 (0.00) 2 (2.15) >0.99
>0.99 d d d
0.485 1 (12.50) 0 (0.00) 0.079
0.919 2 (25.00) 18 (19.35) 0.656
0.148 0 (0.00) 5 (5.38) >0.99
0.031 3 (37.50) 27 (29.03) 0.692
0.260 2 (25.00) 5 (5.38) 0.095
0.917 1 (12.50) 10 (10.75) >0.99
0.049 4 (50.00) 16 (17.20) 0.047
0.206 0 (0.00) 6 (6.45) >0.99
0.672 2 (25.00) 32 (34.41) 0.714
>0.99 0 (0.00) 5 (5.38) >0.99
0.495 0 (0.00) 2 (2.15) >0.99
0.131 4 (50.00) 25 (26.88) 0.222
0.363 2 (25.00) 3 (3.23) 0.049
0.206 1 (12.50) 5 (5.38) 0.399
>0.99 2 (25.00) 19 (20.43) 0.670
0.904 1 (12.50) 17 (18.28) >0.99
ns Z ciprofloxacin-nonsusceptible; COPD Z chronic obstructive
scular accident; CVC Z central venous catheter; DM Z diabetes
serovar B; Serovar C1Z Salmonella enterica serovar C1; Serovar
a serovar D; Serovar Typhi Z Salmonella enterica serovar Typhi;
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USA), and both strands were sequenced using the standard
dideoxynucleotide method in an ABI Prism 377 DNA
sequencer (Applied Biosystems, Foster City, CA, USA).
Sequence similarity searches were performed with the
basic local alignment search tool (BLAST; http://blast.ncbi.
nlm.nih.gov/Blast.cgi).
Scoring algorithm for predicting vascular infections
Chen et al22 designed a simple scoring algorithm for pre-
dicting vascular infections with nontyphoidal Salmonella
bacteremia. In this scoring system, male sex, hypertension,
coronary arterial disease, and S. enterica serovar C1 in-
fections are each assigned þ1 point to form the non-
typhoidal Salmonella vascular infection score. In contrast,
malignancy and immunosuppressive therapy are each
assigned 1 point owing to their negative associations with
vascular infections. A cutoff value of þ1 represents a high
sensitivity (95.0%) and an acceptable specificity (45.3%).22
We reviewed the medical record and imaging report such
as computer tomography to find out the patient gets
vascular infection or not.
Statistical analysis
Categorical variables were described as numbers and per-
centages. The age variable is presented as a mean value
with standard deviation (SD). Categorical variables were
analyzed using the Chi-square test with Yates’ continuity
correction or Fisher’s exact test as appropriate. Continuous
variables were analyzed by the Student two-sample t test
for parametric methods. Logistic regression models were
used to identify independent risk factors. Odds ratios (OR)
and 95% confidence intervals (CI) were analyzed separately
for each of the risk factor variables by the univariate
analysis. Subsequently, all significant variables with
p  0.05 in the univariate analysis were used in the
multivariate analysis of the logistic regression model. All
data were analyzed using the Statistical Package for the
Social Sciences (SPSS) version 21.0 (SPSS Inc., Chicago, IL,
USA).
Results
To describe patient characteristics, comorbidities, invasive
procedure use, and serogroups of isolates, a total of 101
Salmonella blood isolates were collected during the study
period. There were 22 (21.78%) S. enterica serovar B, 5
(4.95%) S. enterica serovar C1, 7 (6.93%) S. enterica serovar
C2, 65 (64.36%) S. enterica serovar D, and 2 (1.98%) S.
enterica serovar Typhi (S. typhi) isolates.
The age distribution of the study population was
62.81  18.65 years. The male-to-female ratio was 64:37
(males, 63.37%, 64/101). There were 49 patients aged 65
years. Table 1 shows the demographic and clinical charac-
teristics according to variables of age and ciprofloxacin
susceptibility among 101 adult patients with Salmonella
enterica bacteremia. The mean ( SD) age of adult patients
<65 years old was 48.29  13.627 years. The mean ( SD)
age of elderly patients 65 years old was 78.22  7.504years. Compared with the <65-year-old adult patients,
more patients older than 65 had heart disease (40.82% vs.
19.23%; p Z 0.031) and renal insufficiency (28.57% vs.
11.54%; pZ 0.049). In contrast, fewer people 65 years old
had S. enterica serovar D bacteremia (53.06% vs. 75.00%;
p Z 0.036). In patients with ciprofloxacin-nonsusceptible
bacteremia, there were more S. enterica serovar C1 and
S. enterica serovar C2 isolates than in the ciprofloxacin-
susceptible groups (C1, 25.00% vs. 3.23%, p Z 0.049; C2,
37.50% vs. 4.30%, p Z 0.010). Comorbidities such as renal
insufficiency (50.00% vs. 17.20%, p Z 0.047) and immuno-
suppressive agent usage (25.00% vs. 3.23%; pZ 0.049) were
more common in the ciprofloxacin-resistant bacteremia
group.
All variables with a p value of 0.05 in the univariate
analysis were considered for inclusion in the logistic
regression model for the multivariate analysis. Table 2
shows the multivariate analysis of risk factors in patients
65 years old and ciprofloxacin-nonsusceptible strains
among adult patients with S. enterica bacteremia deter-
mined through the logistic regression analysis. Multivariate
analysis revealed that the independent factor associated
with 65-year-old elderly patients included renal insuffi-
ciency (OR 3.774; p Z 0.020) and heart disease (OR 2.922;
pZ 0.027). The independent risk factors for ciprofloxacin-
nonsusceptible strains included S. enterica serovar C2 (OR
28.430; p Z 0.032), renal insufficiency (OR 13.927;
p Z 0.032), and immunosuppression agent usage (OR
60.082; p Z 0.006).
Table 3 shows the clinical characteristics of patients,
serogroups, QRDR of all subunits for the DNA gyrase (gyrA)
gene and topoisomerase IV (parC ) gene, and MICs among
the ciprofloxacin-nonsusceptible Salmonella bacteremia.
The most common serogroup in ciprofloxacin-nonsusc-
eptible Salmonella isolates was S. enterica serovar C
(62.50%, 5/8), including two S. enterica serovar C1 and
three S. enterica serovar C2 isolates.
Isolates with the gyrA mutation comprised 87.50% (7/
8), while 62.50% (5/8) of the isolates had the parC muta-
tion, but none had gyrB or parE mutations. The gyrA mu-
tations were manifested as Ser83Phe, Asp87Asn, and
Ser83Tyr. The parC mutations were manifested as
Thr57Ser and Ser80Ile. The two isolates of S. enterica
serovar C1 with Ser83Phe/Asp87Asn gyrA mutation and
Thr57Ser/Ser80Ile parC mutations exhibited high-level
resistance to ciprofloxacin (MIC  4 mg/L). The other
isolates harboring either the gyrA mutation or parC mu-
tation gene presented low-level resistance to ciprofloxa-
cin (MIC Z 2 mg/L).
The similarity of PFGE patterns in eight ciprofloxacin-
nonsusceptible Salmonella blood isolates is presented in
Figure 1. Isolates No.5 and No.6 of S. enterica serovar C1
were considered to belong to the same cluster. Isolates
No.7 and No.8 of S. enterica serovar B were considered to
belong to the same cluster when their similarity coefficient
reached 85%.
We also attempted to match our study participants with
the simple scoring algorithm designed by Chen et al22 to
predict vascular infections with nontyphoidal Salmonella
bacteremia in our study. We found a high sensitivity [100%,
5/(5þ0)] and an acceptable specificity [47.44%, 37/
(41þ37)] of vascular infections in patients.
Table 2 Multivariate analysis of risk factors for 65-year-old elderly patients and ciprofloxacin-nonsusceptible strains among
patients with Salmonella enterica bacteremia.
Demographic and clinical characteristics 65 y elderly patients (n Z 49) Ciprofloxacin-nonsusceptible (n Z 8)
Odds ratio (95% CI) p Odds ratio (95% CI) p
S. enterica serovar C1 d d d 6.036 0.243e150.202 0.273
S. enterica serovar C2 d d d 28.430 1.328e608.699 0.032
S. enterica serovar D 0.557 0.161e1.923 0.354 0.430 0.028e6.600 0.545
Renal insufficiency 3.774 1.230e11.576 0.020 13.927 1.254e154.653 0.032
Heart disease 2.922 1.132e7.543 0.027 d d d
Immunosuppression agent d d d 60.082 3.146e1147.441 0.006
CI Z confidence interval; d Z not available.
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This study had two main objectives. The first objective was
to elucidate the prevalence of S. enterica serogroups. The
second objective was to investigate the difference between
patients with Salmonella bacteremia in those <65 and 65
years old and in those afflicted with ciprofloxacin-
susceptible strains versus those with ciprofloxacin-
nonsusceptible strains.
The serogroup distribution of Salmonella bacteremia
may vary in different geographical localities. In our study,
the most common serogroup of Salmonella bacteremia was
S. enterica serovar D (64.36%, 65/101). The second most
common serogroup was S. enterica serovar B (21.78%, 22/
101), followed by S. enterica serovar C2 (6.93%, 7/101), S.
enterica serovar C1 (4.95%, 5/101), and S. enterica serovar
Typhi (1.98%, 2/101). These results corroborate those of Lin
et al,4 who analyzed patients from northern Taiwan in
2010e2012 and found that the most common Salmonella
serogroup was S. enterica serovar D (68.8%), followed by S.
enterica serovar B (23.4%), S. enterica serovar C2 (6.3%),
and S. enterica serovar C1 (1.6%).
Our findings had some differences from previous reports.
Parry et al2 revealed that serogroups causing bacteremiaTable 3 The clinical characteristics of patients, serogroups, qu
gyrase (gyrA) gene, topoisomerase IV (parC) gene and MICs a
bacteremia.
No Year Sex Age Outcome ICU
stay
DM Heart
disease
Renal
insufficiency
P
m
1 2012 F 77 Survived No Yes No Yes N
2 2013 M 51 Survived No No No No N
3 2012 F 72 Survived Yes Yes No Yes E
4 2013 M 80 Survived Yes No No Yes N
5 2011 M 52 Survived No No Yes No N
6 2013 M 70 Died No No No No N
7 2012 F 63 Survived No Yes Yes Yes N
8 2013 F 54 Survived No Yes Yes No N
*ICU, intensive care unit; DM, diabetes mellitus; E. coli, Escherichia
monella enterica serovar D; Serovar C1, Salmonella enterica serov
phenylalanine; D, aspartic acid; N, asparagine; Y, tyrosine; T, threon
*MICs (mg/L)included S. Enteritidis (47.6%) and S. Typhimurium (14.3%)
for patients from Liverpool, UK. Li et al6 demonstrated that
the serogroups of nontyphoidal Salmonella isolates
included S. enterica serovar B (40.2%), S. enterica serovar D
(30.9%), S. enterica serovar C (26.5%), and S. enterica
serovar E (1.5%) in patients with malignancy from southern
Taiwan. Yen et al8 showed that infections in 31 patients
(39.24%) were due to S. enterica serovar D. Infections were
due to S. enterica serovar B in 24 patients (30.38%) and S.
enterica serovar C in 22 patients (27.85%) from northern
Taiwan in 2001e2003.
Interestingly, Zaidenstein et al23 found that males 60
years of age were more likely to have bacteremia than
females of the same age. They also showed that S. enterica
serovar Enteritidis had the highest incidence in patients’
60 years old. Some studies suggested that the risk factors
were associated with underlying diseases, such as diabetes
mellitus, human immunodeficiency virus infection, and
solid tumor.8,24 However, we found that heart disease and
renal failure were more common in those with Salmonella
bacteremia who were 65 years old. The discrepancies may
vary between different geographical localities or different
study periods. We suggest that separate outbreak in-
vestigations should be performed in each hospital setting,inolone resistance determining region of all subunits for DNA
mong the ciprofloxacin-nonsusceptible Salmonella enterica
oly-
icrobial
Serovar gyrA
mutation
parC
mutation
MICs
to CIP by
Agar dilution
MICs to
CIP by
Vitek 2
o C2 NP T57/S 2 2
o C2 D87/N T57/S 2 2
. coli C2 S83/F T57/S 2 4
o D D87/N NP 2 2
o C1 S83/F,
D87/N
T57/S,
S80/I
 4 8
o C1 S83/F,
D87/N
T57/S,
S80/I
 4 8
o B D87/N NP 2 2
o B S83/Y NP 2 2
coli; Serovar C2, Salmonella enterica serovar C2; Serovar D, Sal-
ar C1; Serovar B, Salmonella enterica serovar B; S, serin ; F,
ine; I, isoleucine; NP, not present; CIP, ciprofloxacin.
Figure 1. Pulse-field gel electrophoresis of ciprofloxacin-nonsusceptible strains of Salmonella blood isolates (eight isolates).
Ciprofloxacin-nonsusceptible Salmonella bacteremia 697and infection control strategies need to be developed to
limit the spread of Salmonella infection.
The nonsusceptible rate of ciprofloxacin resistance in
our study was 7.92% (8/101). In contrast, Wang et al25
showed that the overall rate of ciprofloxacin resistance
among their S. Choleraesuis isolates was 59%, and the
annual rate increased with time from 0% prior to 2000 to
80% in 1996e2004 in northern Taiwan. Liao et al26 found
that there was a significant reduction in the incidence of S.
Choleraesuis bacteremia during 2005e2006 since its peak in
2004 and that the incidence remained low at both in-
stitutions during 2006e2011 in northern Taiwan. In
contrast, the percentage of S. Choleraesuis isolates with
ciprofloxacin resistance was approximately 80% during
2001e2004 and 100% during 2006e2011.26
Chiou et al. revealed that different ciprofloxacin resis-
tance rates of Salmonella enterica serovar Typhi isolates
from Bangladesh and Taiwan. Among the isolates from
Bangladesh, 39.5 % (15/38) were resistant to ciprofloxacin,
and from Taiwan, 0% (0/36) were resistant. We presented
that the two Salmonella enterica serovar Typhi isolates
were susceptible to ciprofloxacin in this study. Our results
were in accord with that reported previously in Taiwan.27
However, Lee et al. presented that there were two Sal-
monella enterica serovar Typhi isolates with complete
resistance to ciprofloxacin (MIC >32 mg/L) from Taiwan in
2011. The two isolates were from one patient who had
recently travelled to India.28
We also found that the clinical characteristics of pa-
tients harboring ciprofloxacin-nonsusceptible isolates were
significantly different from those harboring ciprofloxacin-
susceptible isolates. Patients with ciprofloxacin-
nonsusceptible isolates were more likely to have renal
insufficiency comorbidity and immunosuppressive agent
usage. Chen et al7 reported the highest risk in the elderly
from southern Taiwan with age-related disorders and
younger patients receiving immunosuppressive therapy for
their underlying diseases.
In this study, the eight ciprofloxacin-nonsusceptible
isolates were associated with mutations gyrA and parC to
ciprofloxacin within QRDRs in Salmonella. 87.50% (7/8) of
the isolates had gyrA mutation and 62.50% (5/8) of the
isolates had parC mutation, but none had gyrB and parE
mutations. In contrast, in Malaysia, Karunakaran et al29
detected the qnrS gene in 17/23 (73.91%), and single gyrA
mutations were detected in 6/23 [26.09%; Asp87Tyr(n Z 3), Asp87Asn (n Z 2), and Ser83Phe (n Z 1)]. A parC
(Thr57Ser) mutation was detected in 13/23 (56.52%) of the
isolates coexisting with either a qnrS gene or a gyrA mu-
tation. Although the detected rate of gyrA mutation was
different in our report, the coexisting gyrA and parC mu-
tations presenting high-level ciprofloxacin resistance had
the same results. A first-step mutation reduced the sus-
ceptibility of DNA gyrase to a low level, and additional
mutations in gyrA or mutations in parC could further
augment resistance. The parC alterations played a com-
plementary role in the development of higher-level fluo-
roquinolone-resistance.14,29
One limitation of this study is that it was conducted in a
single medical center and the results may not be applicable
to other hospitals. Another limitation is that the isolates
were only identified as serogroups, such as crude S.
enterica serovar B, S. enterica serovar C1, S. enterica
serovar C2, S. enterica serovar D, or S. Typhi by the con-
ventional biochemical tests and “O” Group typing in the
microbiological laboratory.
In conclusion, this study demonstrates that among adult
patients with Salmonella bacteremia, the risk factors of
65 year-old elderly patients included renal insufficiency
and heart disease. The risk factors of ciprofloxacin-
nonsusceptible strains included S. enterica serovar C2,
renal insufficiency, and immunosuppression agent usage.
Furthermore, the eight ciprofloxacin-nonsusceptible iso-
lates carried gyrA and parC mutations, whereas gyrB and
parEmutations were not found. The isolates with coexisting
Ser83Phe/Asp87Asn gyrA mutation and Thr57Ser/Ser80Ile
parC mutation genes exhibited high-level resistance to
ciprofloxacin (MIC  4 mg/L). Resistance caused by gyrA
and parC mutations among ciprofloxacin-nonsusceptible
isolates poses a major concern.Conflicts of interest
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